Zacks: Analysts Expect Galmed Pharmaceuticals Ltd. (GLMD) Will Post Earnings of -$0.37 Per Share

Brokerages expect Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) to report earnings per share of ($0.37) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Galmed Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.27) and the lowest estimate coming in at ($0.44). Galmed Pharmaceuticals posted earnings of ($0.39) per share in the same quarter last year, which indicates a positive year over year growth rate of 5.1%. The business is expected to issue its next quarterly earnings results on Wednesday, August 2nd.

On average, analysts expect that Galmed Pharmaceuticals will report full-year earnings of ($1.37) per share for the current year, with EPS estimates ranging from ($1.65) to ($1.06). For the next year, analysts expect that the firm will post earnings of ($1.59) per share, with EPS estimates ranging from ($1.74) to ($1.35). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Galmed Pharmaceuticals.

Galmed Pharmaceuticals (NASDAQ:GLMD) last released its quarterly earnings results on Monday, May 15th. The biopharmaceutical company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.13. The firm had revenue of $0.27 million for the quarter, compared to analysts’ expectations of $0.29 million.

A number of equities analysts have commented on the stock. ValuEngine raised shares of Galmed Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. Maxim Group set a $9.00 price objective on shares of Galmed Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, May 15th. Zacks Investment Research raised shares of Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a research note on Tuesday, March 28th. Finally, HC Wainwright dropped their price objective on shares of Galmed Pharmaceuticals from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Tuesday, March 28th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $10.45.

Galmed Pharmaceuticals (GLMD) opened at 6.99 on Tuesday. The company has a 50-day moving average of $5.13 and a 200 day moving average of $4.55. The stock’s market capitalization is $85.05 million. Galmed Pharmaceuticals has a 12 month low of $2.78 and a 12 month high of $7.32.

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. KCG Holdings Inc. purchased a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 20,473 shares of the biopharmaceutical company’s stock, valued at approximately $100,000. KCG Holdings Inc. owned approximately 0.17% of Galmed Pharmaceuticals as of its most recent filing with the SEC. 8.02% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Expect Galmed Pharmaceuticals Ltd. (GLMD) Will Post Earnings of -$0.37 Per Share” was originally reported by Ticker Report and is owned by of Ticker Report. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/2654758/zacks-analysts-expect-galmed-pharmaceuticals-ltd-glmd-will-post-earnings-of-0-37-per-share.html.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:GLMD”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Get a free copy of the Zacks research report on Galmed Pharmaceuticals (GLMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Blue Apron Filed Thursday for Public Offering
Blue Apron Filed Thursday for Public Offering
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Large Auto Lender Checked Just 8% of Incomes for Applicants
Large Auto Lender Checked Just 8% of Incomes for Applicants


Leave a Reply

© 2006-2017 Ticker Report. Google+.